AtomVie Global Radiopharma has entered a strategic partnership with Ionetix to improve access to clinical-grade actinium-225 (Ac-225) for its global partners.
Under this agreement, Ionetix will supply current Good Manufacturing Practice (cGMP)-grade Ac-225, an alpha-emitting radioisotope, to AtomVie for the development and manufacturing of its AtomVie's radiopharmaceutical programs. AtomVie is preparing to launch its new radiopharmaceutical manufacturing facility in Hamilton, Ontario, Canada.
Through this collaboration, AtomVie said it aims to provide better value to its clients and partners by integrating a dependable isotope supply network directly into its development and manufacturing services and expanding its pipeline of Ac-225-based assets.
